Liquid Biopsy for Prostate and Bladder Cancer: Progress and Pitfalls

被引：13

作者：

Groen, Levi ^{[1
]}

Schalken, Jack ^{[1
,2
]}

机构：

[1] Radboudumc, Radboud Inst Life Sci, Nijmegen, Netherlands

[2] Radboudumc, Res Inst Life Sci, Nijmegen, Netherlands

来源：

EUROPEAN UROLOGY FOCUS | 2022年 / 8卷 / 04期

关键词：

Prostate cancer; Bladder cancer; Liquid biopsy; Precision therapy;

D O I：

10.1016/j.euf.2022.08.013

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Urinary liquid biopsy (LB) tests have contributed to reducing overtreatment and improv-ing the detection of bladder and prostate cancer. Circulating tumor cells, DNA, and RNA are the focus of next-generation blood-based LB tests. These tests aim to stratify risk according to the detection of resistance and recurrence markers in patients with meta-static disease. The costs, lack of standardization, reimbursement challenges, and special-ized workflows associated with characterization of blood-derived biomarkers are the primary barriers to their clinical implementation. This review provides an overview of the successes and pitfalls of LB-based tests for bladder and prostate cancer.Patient summary: Urinary and blood-based liquid biopsy tests are minimally invasive and highly efficacious in detecting clinically significant cancer.(c) 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).

引用

页码：904 / 906

页数：3

共 10 条

[1] Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer [J].

Annala, Matti ;

Vandekerkhove, Gillian ;

Khalaf, Daniel ;

Taavitsainen, Sinja ;

Beja, Kevin ;

Warner, Evan W. ;

Sunderland, Katherine ;

Kollmannsberger, Christian ;

Eigl, Bernhard J. ;

Finch, Daygen ;

Oja, Conrad D. ;

Vergidis, Joanna ;

Zulfiqar, Muhammad ;

Azad, Arun A. ;

Nykter, Matti ;

Gleave, Martin E. ;

Wyatt, Alexander W. ;

Chi, Kim N. .

CANCER DISCOVERY, 2018, 8 (04) :444-457

[2]

Ashworth TR., 1869, Med. J. Aust, V14, P146

[3] Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer [J].

Beije, N. ;

de Kruijff, I. E. ;

de Jong, J. J. ;

Klaver, S. O. ;

de Vries, P. ;

Jacobs, R. A. L. ;

Somford, D. M. ;

te Slaa, E. ;

van der Heijden, A. G. ;

Witjes, J. Alfred ;

Fossion, L. M. C. L. ;

Boeve, E. R. ;

van der Hoeven, J. ;

van Melick, H. H. E. ;

Wijburg, C. J. ;

Bickerstaffe, H. ;

Martens, J. W. M. ;

de Wit, R. ;

Kraan, J. ;

Sleijfer, S. ;

Boormans, J. L. .

ESMO OPEN, 2022, 7 (02)

[4]

Bronkhorst Abel Jacobus, 2019, Biomol Detect Quantif, V17, P100087, DOI 10.1016/j.bdq.2019.100087

[5] Liquid biopsy in bladder cancer: State of the art and future perspectives [J].

Crocetto, Felice ;

Barone, Biagio ;

Ferro, Matteo ;

Busetto, Gian Maria ;

La Civita, Evelina ;

Buonerba, Carlo ;

Di Lorenzo, Giuseppe ;

Terracciano, Daniela ;

Schalken, Jack A. .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 170

[6] Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis [J].

Matuszczak, Milena ;

Schalken, Jack A. ;

Salagierski, Maciej .

CANCERS, 2021, 13 (13)

[7] Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer [J].

Sperger, Jamie M. ;

Emamekhoo, Hamid ;

McKay, Rana R. ;

Stahlfeld, Charlotte N. ;

Singh, Anupama ;

Chen, Xinyi E. ;

Kwak, Lucia ;

Gilsdorf, Cole S. ;

Wolfe, Serena K. ;

Wei, Xiao X. ;

Silver, Rebecca ;

Zhang, Zhenwei ;

Morris, Michael J. ;

Bubley, Glenn ;

Feng, Felix Y. ;

Scher, Howard, I ;

Rathkopf, Dana ;

Dehm, Scott M. ;

Choueiri, Toni K. ;

Halabi, Susan ;

Armstrong, Andrew J. ;

Wyatt, Alexander W. ;

Taplin, Mary-Ellen ;

Zhao, Shuang G. ;

Lang, Joshua M. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) :2926-+

[8] Serum microRNA as liquid biopsy biomarker for the prediction of oncological outcomes in patients with bladder cancer [J].

Urabe, Fumihiko ;

Matsuzaki, Juntaro ;

Ito, Kagenori ;

Takamori, Hajime ;

Tsuzuki, Shunsuke ;

Miki, Jun ;

Kimura, Takahiro ;

Egawa, Shin ;

Nakamura, Eijiro ;

Matsui, Yoshiyuki ;

Fujimoto, Hiroyuki ;

Yamamoto, Yusuke ;

Ochiya, Takahiro .

INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (09) :968-976

[9] Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer [J].

Vandekerkhove, Gillian ;

Lavoie, Jean-Michel ;

Annala, Matti ;

Murtha, Andrew J. ;

Sundahl, Nora ;

Walz, Simon ;

Sano, Takeshi ;

Taavitsainen, Sinja ;

Ritch, Elie ;

Fazli, Ladan ;

Hurtado-Coll, Antonio ;

Wang, Gang ;

Nykter, Matti ;

Black, Peter C. ;

Todenhoefer, Tilman ;

Ost, Piet ;

Gibb, Ewan A. ;

Chi, Kim N. ;

Eigl, Bernhard J. ;

Wyatt, Alexander W. .

NATURE COMMUNICATIONS, 2021, 12 (01)

[10] Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer [J].

Zhang, Jingsong ;

Cunningham, Jessica J. ;

Brown, Joel S. ;

Gatenby, Robert A. .

NATURE COMMUNICATIONS, 2017, 8

← 1 →